dexamfetamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anorexics	841	51-64-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dextroamphetamine S-Amphetamine D-Amphetamine dexadrine dexamfetamine dextroamphetamine sulfate dextroamphetamine saccharate dextroamphetamine adipate dextroamphetamine resin complex	The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic. Molecular weight: 135.21 Formula: C9H13N CLOGP: 1.74 LIPINSKI: 0 HAC: 1 HDO: 1 TPSA: 26.02 ALOGS: -1.89 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dextroamphetamine
S-Amphetamine
D-Amphetamine
dexadrine
dexamfetamine
dextroamphetamine sulfate
dextroamphetamine saccharate
dextroamphetamine adipate
dextroamphetamine resin complex

The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.

Molecular weight: 135.21
Formula: C9H13N
CLOGP: 1.74
LIPINSKI: 0
HAC: 1
HDO: 1
TPSA: 26.02
ALOGS: -1.89
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
15	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	0	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	40 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.40 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	75 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Sept. 9, 1955	FDA	UCB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	520.34	36.42	179	529	101445	2255932
Prescribed overdose	453.78	36.42	76	632	1748	2355629
Product quality issue	192.74	36.42	51	657	10778	2346599
Inappropriate schedule of product administration	172.73	36.42	48	660	12156	2345221
Disturbance in attention	156.46	36.42	38	670	5647	2351730
Product substitution issue	140.01	36.42	34	674	5035	2352342
Anxiety	123.81	36.42	46	662	29313	2328064
Feeling abnormal	110.59	36.42	40	668	23541	2333836
Fatigue	93.34	36.42	52	656	84821	2272556
Somnolence	88.61	36.42	34	674	23451	2333926
Depression	86.09	36.42	35	673	28097	2329280
Weight decreased	78.98	36.42	33	675	28338	2329039
Rhabdomyolysis	70.44	36.42	21	687	6683	2350694
Insomnia	68.38	36.42	29	679	25758	2331619
Product physical issue	67.57	36.42	14	694	996	2356381
Condition aggravated	65.53	36.42	30	678	31949	2325428
Therapeutic product effect decreased	64.51	36.42	22	686	10767	2346610
Agitation	64.00	36.42	22	686	11029	2346348
Headache	58.83	36.42	38	670	80141	2277236
Neuroleptic malignant syndrome	57.50	36.42	14	694	2066	2355311
Off label use	56.73	36.42	36	672	73562	2283815
Tremor	53.92	36.42	23	685	20638	2336739
Nausea	53.90	36.42	41	667	112148	2245229
Overdose	51.40	36.42	22	686	19885	2337492
Product use issue	50.72	36.42	19	689	12150	2345227
Dry mouth	49.96	36.42	17	691	8236	2349141
Unevaluable event	48.72	36.42	17	691	8874	2348503
No adverse event	47.57	36.42	17	691	9511	2347866
Paranoia	47.28	36.42	12	696	2095	2355282
Hypothermia	47.05	36.42	12	696	2136	2355241
Serotonin syndrome	45.57	36.42	13	695	3527	2353850
Hypertension	44.71	36.42	22	686	27339	2330038
Therapeutic response unexpected	44.46	36.42	13	695	3846	2353531
Dizziness	40.89	36.42	27	681	58638	2298739
Migraine	38.49	36.42	15	693	10638	2346739
Decreased appetite	37.78	36.42	20	688	28871	2328506
Malaise	37.31	36.42	25	683	55560	2301817
Bruxism	36.50	36.42	8	700	741	2356636

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	350.59	51.41	131	486	63670	1682494
Prescribed overdose	223.13	51.41	44	573	1726	1744438
Aggression	184.41	51.41	50	567	8065	1738099
Product substitution issue	137.25	51.41	33	584	3253	1742911
Product quality issue	130.86	51.41	36	581	6057	1740107
Anxiety	109.00	51.41	39	578	15488	1730676
Insomnia	103.46	51.41	38	579	16238	1729926
Inappropriate schedule of product administration	97.50	51.41	30	587	7429	1738735
Oppositional defiant disorder	91.71	51.41	13	604	57	1746107
Abnormal behaviour	89.19	51.41	27	590	6315	1739849
Decreased eye contact	85.94	51.41	12	605	46	1746118
Psychomotor hyperactivity	78.79	51.41	19	598	1874	1744290
Bruxism	78.68	51.41	14	603	303	1745861
Feeling abnormal	77.96	51.41	28	589	11138	1735026
Coordination abnormal	77.86	51.41	18	599	1479	1744685
Suicidal ideation	77.36	51.41	26	591	8492	1737672
Sydenham's chorea	75.30	51.41	9	608	4	1746160
Somnolence	73.77	51.41	30	587	16709	1729455
Posterior reversible encephalopathy syndrome	72.81	51.41	17	600	1458	1744706
Impulsive behaviour	71.65	51.41	14	603	510	1745654
Depression	70.46	51.41	29	588	16640	1729524
Sleep disorder	68.82	51.41	20	597	4043	1742121
Therapeutic product effect decreased	68.30	51.41	22	595	6275	1739889
Disturbance in attention	68.01	51.41	20	597	4214	1741950
Crying	67.55	51.41	16	601	1459	1744705
Speech disorder	66.60	51.41	20	597	4528	1741636
Headache	64.38	51.41	34	583	34342	1711822
Homicidal ideation	63.16	51.41	13	604	618	1745546
Fatigue	62.16	51.41	38	579	50743	1695421
No adverse event	59.85	51.41	19	598	5163	1741001
Educational problem	57.51	51.41	10	607	188	1745976
Agitation	56.25	51.41	22	595	11004	1735160
Depressed mood	56.19	51.41	16	601	3000	1743164
Dyskinesia	52.46	51.41	16	601	3803	1742361
Mood altered	52.17	51.41	14	603	2108	1744056

Pharmacologic Action:

Source	Code	Description
ATC	N06BA02	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics
FDA EPC	N0000175739	Central Nervous System Stimulant
FDA PE	N0000175729	Central Nervous System Stimulation
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D000697	Central Nervous System Stimulants
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Narcolepsy	indication	60380001	DOID:8986
Attention deficit hyperactivity disorder	indication	406506008
Gilles de la Tourette's syndrome	contraindication	5158005	DOID:11119
Dependent drug abuse	contraindication	6525002
Bipolar disorder	contraindication	13746004	DOID:3312
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Feeling agitated	contraindication	24199005
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Anorexia nervosa	contraindication	56882008	DOID:8689
Aggressive behavior	contraindication	61372001
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Arteriosclerotic vascular disease	contraindication	72092001
Cardiomyopathy	contraindication	85898001	DOID:0050700
Weight loss	contraindication	89362005
Structural disorder of heart	contraindication	128599005
Seizure disorder	contraindication	128613002
Motor tic disorder	contraindication	230337001
Cerebrovascular accident	contraindication	230690007
Mania	contraindication	231494001
Cardiovascular event risk	contraindication	395112001
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Myocardial infarction in recovery phase	contraindication	418044006
Hypertensive urgency	contraindication	443482000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.89	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
12.5MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	6913768	May 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
12.5MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	9173857	May 12, 2026	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
12.5MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	June 20, 2020	NEW PRODUCT
3.125MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	June 20, 2020	NEW PRODUCT
6.25MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	June 20, 2020	NEW PRODUCT
9.375MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	June 20, 2020	NEW PRODUCT
12.5MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
3.125MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
6.25MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
9.375MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	Sept. 13, 2022	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
12.5MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY
3.125MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY
6.25MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY
9.375MG	MYDAYIS	SHIRE DEV LLC	N022063	June 20, 2017	RX	CAPSULE, EXTENDED RELEASE	ORAL	March 13, 2023	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	RELEASING AGENT	Ki	6.68	WOMBAT-PK	CHEMBL
Synaptic vesicular amine transporter	Transporter	Q05940	VMAT2_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Ki	7	IUPHAR	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN		Ki	4.84	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.24	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.18	PDSP
Trace amine-associated receptor 1	GPCR	Q96RJ0	TAAR1_HUMAN		EC50	6.87	WOMBAT-PK
Cocaine- and amphetamine-regulated transcript protein	Transcription factor	Q16568	CART_HUMAN				WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN				WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN				WOMBAT-PK
Serotonin (5-HT) receptor	GPCR		5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT 5HT2A_RAT 5HT2B_RAT 5HT2C_RAT 5HT3A_RAT 5HT3B_RAT 5HT4R_RAT 5HT5A_RAT 5HT5B_RAT 5HT6R_RAT 5HT7R_RAT		Kd	5.35	CHEMBL
Trace amine-associated receptor 1	GPCR		TAAR1_MACMU		EC50	6	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		IC50	5.31	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme		AOFA_RAT		Ki	4.91	CHEMBL
Trace amine-associated receptor 1	GPCR		TAAR1_RAT		EC50	7.25	CHEMBL
Trace amine-associated receptor 1	GPCR		TAAR1_MOUSE		EC50	8.70	CHEMBL

External reference:

ID	Source
D003913	MESH_DESCRIPTOR_UI
4019978	VUID
N0000148062	NUI
C0011812	UMLSCUI
D02078	KEGG_DRUG
387278002	SNOMEDCT_US
50868004	SNOMEDCT_US
4019978	VANDF
001793	NDDF
3288	RXNORM
d00804	MMSL
5826	PUBCHEM_CID
CHEMBL612	ChEMBL_ID
CHEMBL1200782	ChEMBL_ID
G83415V073	UNII
350708-40-6	SECONDARY_CAS_RN
1430	INN_ID
1WE	PDB_CHEM_ID
DB01576	DRUGBANK_ID
2147	IUPHAR_LIGAND_ID
CHEMBL3544971	ChEMBL_ID
CHEMBL3989844	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1328	CAPSULE, EXTENDED RELEASE	1.25 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1328	CAPSULE, EXTENDED RELEASE	1.25 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1329	CAPSULE, EXTENDED RELEASE	2.50 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1329	CAPSULE, EXTENDED RELEASE	2.50 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1330	CAPSULE, EXTENDED RELEASE	3.75 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1330	CAPSULE, EXTENDED RELEASE	3.75 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1331	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1331	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1332	CAPSULE, EXTENDED RELEASE	6.25 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1332	CAPSULE, EXTENDED RELEASE	6.25 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1333	CAPSULE, EXTENDED RELEASE	7.50 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1333	CAPSULE, EXTENDED RELEASE	7.50 mg	ORAL	NDA AUTHORIZED GENERIC	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1486	CAPSULE	1.25 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1486	CAPSULE	1.25 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1487	CAPSULE	2.50 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1487	CAPSULE	2.50 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1488	CAPSULE	3.75 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1488	CAPSULE	3.75 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1489	CAPSULE	5 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1489	CAPSULE	5 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1490	CAPSULE	6.25 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1490	CAPSULE	6.25 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1491	CAPSULE	7.50 mg	ORAL	ANDA	20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	4	0115-1491	CAPSULE	7.50 mg	ORAL	ANDA	20 sections
Dextroamphetamine SulfateExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1702	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	NDA AUTHORIZED GENERIC	14 sections
Dextroamphetamine SulfateExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1703	CAPSULE, EXTENDED RELEASE	10 mg	ORAL	NDA AUTHORIZED GENERIC	14 sections
Dextroamphetamine SulfateExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1704	CAPSULE, EXTENDED RELEASE	15 mg	ORAL	NDA AUTHORIZED GENERIC	14 sections
Dextroamphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	0115-9927	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	NDA AUTHORIZED GENERIC	15 sections
Dextroamphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	0115-9928	CAPSULE, EXTENDED RELEASE	10 mg	ORAL	NDA AUTHORIZED GENERIC	15 sections
Dextroamphetamine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	0115-9929	CAPSULE, EXTENDED RELEASE	15 mg	ORAL	NDA AUTHORIZED GENERIC	15 sections